中文 | English
Return
Total: 86 , 1/9
Show Home Prev Next End page: GO
MeSH:(Non-alcoholic Fatty Liver Disease*)

5.Cardiovascular Risk in Patients with Non-alcoholic Fatty Liver Disease.

Hak Soo KIM ; Yong Kyun CHO

The Korean Journal of Gastroenterology 2017;69(6):333-340

6.Lobeglitazone, a Novel Thiazolidinedione, Improves Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: Its Efficacy and Predictive Factors Related to Responsiveness.

Yong Ho LEE ; Jae Hyeon KIM ; So Ra KIM ; Heung Yong JIN ; Eun Jung RHEE ; Young Min CHO ; Byung Wan LEE

Journal of Korean Medical Science 2017;32(1):60-69

8.The Immune Landscape in Nonalcoholic Steatohepatitis.

Sowmya NARAYANAN ; Fionna A SURETTE ; Young S HAHN

Immune Network 2016;16(3):147-158

9.The role of hepatic macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.

Ji Young CHA ; Da Hyun KIM ; Kyung Hee CHUN

Laboratory Animal Research 2018;34(4):133-139

10.Pathologic Impact of Insulin Resistance and Sensitivity on the Severity of Liver Histopathology in Pediatric Non-Alcoholic Steatohepatitis.

Byung Han PARK ; Jung Min YOON ; Ja Hye KIM ; Jin Hwa MOON ; Young Ho LEE ; Se Min JANG ; Yong Joo KIM

Yonsei Medical Journal 2017;58(4):756-762

Sort by Result Analysis

Display Mode

Output Records




File Type





Total: 86 , 1/9 Show Home Prev Next End page: GO